product summary
Loading...
company name :
R&D Systems
product type :
antibody
product name :
LMAN2 Antibody (04) [HRP]
catalog :
NBP3-05831H
quantity :
0.1 ml
price :
369 USD
clonality :
monoclonal
host :
mouse
conjugate :
HRP
clone name :
04
reactivity :
human
application :
ELISA
more info or order :
product information
brand :
Novus
master code :
NBP3-05831H
SKU :
NBP3-05831H
product name :
LMAN2 Antibody (04) [HRP]
sizes available :
0.1 ml
description :
The LMAN2 Antibody (04) [HRP] from NBP3-05831H is a 6.7e-05 antibody to . This antibody reacts with human.
target :
LMAN2
category :
Primary Antibodies
buffer :
PBS
clonality :
Monoclonal
clone :
04
conjugate :
HRP
all_available conjugate :
DyLight 680;Alexa Fluor 647;Allophycocyanin;Alexa Fluor 750;DyLight 350;CoraFluor 1;FITC;mFluor Violet 500 SE;Alexa Fluor 488;HRP
dilution :
ELISA, Sandwich ELISA Capture
host :
Mouse
immunogen :
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human LMAN2 (Uniprot#: Q12907; Asp45-Arg322).
isotype :
IgG
purity :
Protein A purified
species :
Human
gene symbol :
LMAN2
applications :
ELISA,Sandwich ELISA Capture
USD :
369 USD
alt names :
C5orf8, chromosome 5 open reading frame 8, Glycoprotein GP36b, GP36B, Lectin mannose-binding 2, lectin, mannose-binding 2, vesicular integral protein of 36 kDa, vesicular integral-membrane protein VIP36, VIP36
storage :
Store at 4C in the dark.
more info or order :
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
related products
browse more products
questions and comments
